4.3 Article

The presence of sinusoidal CD163+ macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer

Journal

VIRCHOWS ARCHIV
Volume 461, Issue 6, Pages 639-646

Publisher

SPRINGER
DOI: 10.1007/s00428-012-1338-4

Keywords

Breast cancer; Macrophages; Natural killer cells; Lymph nodes

Categories

Ask authors/readers for more resources

As macrophages are some of the first cells to encounter metastatic tumor cells in sentinel lymph nodes (SLN) and natural killer (NK) cells are critical to the cytotoxicity of abnormal cells, we sought to determine if these cell populations were altered in the presence of nodal metastasis. We used immunohistochemistry to assess the SLN of 47 patients with breast cancer (36 with nodal metastasis and 11 without nodal metastasis) and 10 control lymph nodes. We assessed metastatic areas and nonmetastatic areas separately for CD163, a marker of macrophages, and ANK-1, a marker for precursors of activated NK cells. Positively stained cells were manually counted in multiple high-power fields and averaged. Groups were compared with the Kruskal-Wallis test. Spearman rank order test was used for correlations. There was a lower frequency of CD163(+) macrophages in the SLN of patients with breast cancer (median, 11.0 %; range, 4.1-20.4 %) than controls (median, 16.5 %; range, 8.9-19.6 %; p = 0.002). There were no differences in the expression of ANK between patients with cancer (median, 1.4 %; range, 0.23-6.3 %) and controls (median, 1.5 %; range, 0.60-5.4 %; p = 0.5). In patients with nodal metastasis, the accumulation of CD163(+) cells in the sinuses correlated negatively with CD8(+) tumor-infiltrating lymphocytes (r (2) = 0.23; p = 0.001). These results suggest that the reduction of CD163(+) macrophages in the sinuses of the SLN is associated with nodal metastasis and may have a role in regional immunity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma

Daniel H. Ahn, Pedro Luiz Serrano Uson Junior, Peter Masci, Heidi Kosiorek, Thorvardur R. Halfdanarson, Kabir Mody, Hani Babiker, Thomas DeLeon, Mohamad Bassam Sonbol, Gregory Gores, Rory Smoot, Tanios Bekaii-Saab, Amit Mahipal, Aaron Mansfield, Nguyen H. Tran, Joleen M. Hubbard, Mitesh J. Borad

Summary: Ponatinib as a single agent in treating BTC with FGFR alterations showed limited clinical activity but was tolerable. The study provides valuable information for the further development of ponatinib in BTC treatment.

INVESTIGATIONAL NEW DRUGS (2022)

Article Oncology

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

S. Peters, A. Scherpereel, R. Cornelissen, Y. Oulkhouir, L. Greillier, M. A. Kaplan, T. Talbot, I Monnet, S. Hiret, P. Baas, A. K. Nowak, N. Fujimoto, A. S. Tsao, A. S. Mansfield, S. Popat, X. Zhang, N. Hu, D. Balli, T. Spires, G. Zalcman

Summary: In patients with unresectable malignant pleural mesothelioma, first-line nivolumab plus ipilimumab showed continued long-term survival benefit over chemotherapy with a manageable safety profile, based on 3 years of follow-up data.

ANNALS OF ONCOLOGY (2022)

Article Oncology

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma

Arun Kanakkanthara, Xiaonan Hou, Thomas L. Ekstrom, Valentina Zanfagnin, Amelia M. Huehls, Rebecca L. Kelly, Husheng Ding, Melissa C. Larson, George Vasmatzis, Ann L. Oberg, Scott H. Kaufmann, Aaron S. Mansfield, S. John Weroha, Larry M. Karnitz

CANCER RESEARCH (2022)

Article Gastroenterology & Hepatology

FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations

Pedro Luiz Serrano Uson, Thomas T. DeLeon, James M. Bogenberger, Rish K. Pai, Heidi E. Kosiorek, Jun Yin, Daniel H. Ahn, Mohammad Bassam Sonbol, Tanios Bekaii-Saab, Aaron S. Mansfield, Kenneth Buetow, Gregory J. Gores, Rory Smoot, George Vasmatzis, Benjamin R. Kipp, Amit Mahipal, Alexander T. Baker, Hani Babiker, Oumar Barro, Chelsae Dumbauld, Yumei Zhou, Faaiq N. Aslam, Michael Barrett, Bertram Jacobs, Nathalie Meurice, Mansi Arora, Joachim Petit, Natalie Elliott, Bolni Nagalo, Marcela A. Salomao, Mitesh J. Borad

Summary: Immunohistochemistry staining with two antibodies against FGFR2 showed high accuracy and specificity, but only moderate sensitivity, for detecting FGFR2 genomic alterations in cholangiocarcinoma. However, there were no significant differences in clinical outcomes including overall survival, progression-free survival, and time-to-tumor recurrence between patients with positive or negative FGFR2 staining in a median follow-up of 72 months.

DIGESTIVE DISEASES AND SCIENCES (2022)

Meeting Abstract Oncology

Genomic predictors of benefit from checkpoint inhibition in neuroendocrine carcinoma

Patrick Walsh McGarrah, Jennifer Gile, Alex John Liu, Aaron Scott Mansfield, Konstantinos Leventakos, Aakash Desai, Sri Harsha Tella, Bassam Bassam Sonbol, Jason S. Starr, Timothy J. Hobday, Thorvardur Ragnar Halfdanarson

JOURNAL OF CLINICAL ONCOLOGY (2022)

Review Oncology

New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options

Anne S. Tsao, Harvey Pass, Andreas Rimner, Aaron S. Mansfield

Summary: Malignant pleural mesothelioma (MPM) is a rare malignancy with limited treatment options. Recent advances have led to changes in treatment standards, including the use of a novel biomedical device in combination with platinum-pemetrexed and the inclusion of immunotherapy as a frontline treatment option. Proper identification of the MPM histology is crucial in determining the optimal treatment plan. Immunotherapy can benefit all MPM patients and should be considered at some point during treatment. Ongoing research is focusing on defining frontline therapy in the unresectable setting and addressing immunotherapy refractory cases.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Ti Wen, Whitney Barham, Ying Li, Henan Zhang, Joanina K. Gicobi, Jacob B. Hirdler, Xin Liu, Hyoungjun Ham, Kodi E. Peterson Martinez, Fabrice Lucien, Roxane R. Lavoie, Hu Li, Cristina Correia, Dileep D. Monie, Zesheng An, Susan M. Harrington, Xiaosheng Wu, Ruifeng Guo, Roxana S. Dronca, Aaron S. Mansfield, Yiyi Yan, Svetomir N. Markovic, Sean S. Park, Jie Sun, Hong Qin, Minetta C. Liu, George Vasmatzis, Daniel D. Billadeau, Haidong Dong

CANCER IMMUNOLOGY RESEARCH (2022)

Article Oncology

Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors

Anja C. Roden, Sagar Rakshit, Geoffrey B. Johnson, Sarah M. Jenkins, Aaron S. Mansfield

Summary: The expression of SSTR2 in neuroendocrine tumors and carcinomas plays a role in imaging studies and guiding therapy. In this study, SSTR2 expression in TET was correlated with 68Ga-DOTATATE PET/CT or 68Ga-DOTATATE PET/MR results and treatment outcome. The findings suggest that 68Ga-DOTATATE PET scans are useful in identifying TET patients who may be amenable to treatment with somatostatin analogues.

FRONTIERS IN ONCOLOGY (2022)

Editorial Material Oncology

Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases

Anuhya Kommalapati, Aaron S. Mansfield

Summary: The activity of KRAS inhibitors against brain metastases is not well studied. Recent preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial suggest that adagrasib (MRTX849) has the potential to penetrate the central nervous system and provide control of KRAS(G12C) brain metastases.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Lower Exome Sequencing Coverage of Ancestrally African Patients in The Cancer Genome Atlas

Daniel P. Wickland, Mark E. Sherman, Derek C. Radisky, Aaron S. Mansfield, Yan W. Asmann

Summary: In the United States, cancer disparities among Black and African American individuals are affected by genetic factors. This study compared the qualities of germline and tumor exomes between African and European patients in The Cancer Genome Atlas. The results showed that African patients had lower sequencing depth, leading to underdetection and lower quality of variants. Consideration of epidemiological factors is crucial for future genomics studies.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Article Oncology

Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors

Farhad Kosari, Maria Disselhorst, Jun Yin, Tobias Peikert, Julia Udell, Sarah Johnson, James Smadbeck, Stephen Murphy, Alexa McCune, Giannoula Karagouga, Aakash Desai, Janet Schaefer-Klein, Mitesh J. Borad, John Cheville, George Vasmatzis, Paul Baas, Aaron S. Mansfield

Summary: This study found that the interaction between tumor junction burdens and antigen presentation gene sets in mesothelioma patients is associated with overall survival, providing further insight into the potential mechanisms of immunotherapy.

JOURNAL OF THORACIC ONCOLOGY (2022)

Letter Oncology

RE: Lower Exome Sequencing Coverage of Ancestrally African Patients in the Cancer Genome Atlas Response

Daniel P. Wickland, Mark E. Sherman, Derek C. Radisky, Aaron S. Mansfield, Yan W. Asmann

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Article Multidisciplinary Sciences

Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology

James M. Dolezal, Andrew Srisuwananukorn, Dmitry Karpeyev, Siddhi Ramesh, Sara Kochanny, Brittany Cody, Aaron S. Mansfield, Sagar Rakshit, Radhika Bansal, Melanie C. Bois, Aaron O. Bungum, Jefree J. Schulte, Everett E. Vokes, Marina Chiara Garassino, Aliya N. Husain, Alexander T. Pearson

Summary: A model's ability to express its own predictive uncertainty is crucial in maintaining clinical user confidence in real-world medical settings. This study presents a clinically-oriented approach to quantify uncertainty in cancer digital histopathology, using dropout to estimate uncertainty and establishing cutoffs for low- and high-confidence predictions based on threshold calculation on training data.

NATURE COMMUNICATIONS (2022)

Meeting Abstract Oncology

Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib.

A. Dimou, Y. -C. Lo, K. Halling, A. S. Mansfield

JOURNAL OF THORACIC ONCOLOGY (2022)

Article Oncology

Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy

Pedro Luiz Serrano Uson Junior, Umair Majeed, Jun Yin, Gehan Botrus, Mohamad Bassam Sonbol, Daniel H. Ahn, Jason S. Starr, Jeremy C. Jones, Hani Babiker, Samantha R. Inabinett, Natasha Wylie, Ashton W. R. Boyle, Tanios S. Bekaii-Saab, Gregory J. Gores, Rory Smoot, Michael Barrett, Bolni Nagalo, Nathalie Meurice, Natalie Elliott, Joachim Petit, Yumei Zhou, Mansi Arora, Chelsae Dumbauld, Oumar Barro, Alexander Baker, James Bogenberger, Kenneth Buetow, Aaron Mansfield, Kabir Mody, Mitesh J. Borad

Summary: This study aimed to evaluate the prognostic value of pretreatment circulating tumor DNA (ctDNA) in metastatic biliary tract cancers (BTCs) treated with platinum-based chemotherapy. The results showed that DCAF > 3% was associated with worse overall survival (OS). Stratifying DCAF into quartiles, DCAF > 10% was significantly related to worse progression-free survival (PFS) and OS. Each 1% increase in ctDNA was associated with a decrease in survival probabilities.

JCO PRECISION ONCOLOGY (2022)

No Data Available